Harvard Apparatus Regenerative Technology Inc (HRGN) Stock Analysis
Verdict: AVOID
Severe liquidity strain with ~4 months cash runway and 0.26 current ratio poses acute dilution risk despite recent $704k revenue entry.
Investment score: 30/100
Analysis as of
Is Harvard Apparatus Regenerative Technology Inc stock worth reviewing? The TradeMates thesis
The TradeMates model identifies acute liquidity distress and imminent equity dilution risk for HRGN, given $1.35M in cash versus a $3.83M annual burn rate. High valuation metrics (P/S 47.07x) and weak balance sheet metrics outweigh recent technical momentum.
7-factor investment score
- Valuation: 20/100 (weight 20%)
- Financial Health: 10/100 (weight 15%)
- Technical Momentum: 65/100 (weight 15%)
- Earnings Quality: 25/100 (weight 15%)
- Insider Sentiment: 55/100 (weight 10%)
- Analyst Consensus: 20/100 (weight 10%)
- Risk-Adjusted Return: 20/100 (weight 15%)
Harvard Apparatus Regenerative Technology Inc opportunities and risks
What speaks for HRGN
- Initial revenue milestone reached in 2025
What speaks against HRGN
- Severe liquidity depletion and impending equity dilution
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| HRGN | n/a | 47.1x | n/a | -5.7% | -778.0% | -9.0% |
| HOWL | n/a | 2.2x | n/a | 86.4% | -164.8% | -66.6% |
| ANVS | n/a | 0.0x | n/a | 0.0% | 0.0% | -91.8% |
| MGX | n/a | 3.2x | n/a | 74.3% | -689.2% | -196.5% |
| MCRB | n/a | 22.7x | n/a | 82.6% | -1192.9% | -119.9% |
| CLCS | n/a | 0.0x | n/a | 0.0% | 0.0% | -7.0% |
| Peer median | n/a | 2.2x | n/a | 74.3% | -164.8% | -91.8% |
Frequently asked questions about Harvard Apparatus Regenerative Technology Inc (HRGN)
Is HRGN stock a good investment?
The TradeMates model rates Harvard Apparatus Regenerative Technology Inc as AVOID with an investment score of 30/100. The TradeMates model identifies acute liquidity distress and imminent equity dilution risk for HRGN, given $1.35M in cash versus a $3.83M annual burn rate. High valuation metrics (P/S 47.07x) and weak balance sheet metrics outweigh recent technical momentum. This is algorithmic model output, not personal investment advice.
Is HRGN stock a buy?
The TradeMates model verdict for HRGN is AVOID with an investment score of 30/100. Treat this as a model signal to review, not a personal buy recommendation.